DV
Dividend Vision

LRMR — Larimar Therapeutics Inc

Larimar Therapeutics Inc (LRMR)

Total return is -98.2% over the past 12.2 years, 483.8 points behind SPY at 385.6%. Its deepest 1-year drawdown was 48.7%.

Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases using its cell penetrating peptide technology platform, with its lead candidate CTI-1601 currently in Phase 2 testing for Friedreich's ataxia. The company does not currently distribute dividends. This security may appeal to investors seeking exposure to early-stage biotech development, though it carries the risks inherent to pre-revenue clinical-stage companies.

LRMR key facts

Asset type
Stock
Asset class
Equity
Inception date
06/19/2014
Last close
$4.36
Market cap
$397,871,648
Average volume
1183071.0
Payment date
05/29/2020
Beta
0.837
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.19